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Introduction {#sec001}
============

The medically important polyphyletic genus *Candida* contains more than 300 different yeast species, around 20 of which are regularly reported from human infections ranging in spectrum from superficial mycoses to deep-seated and disseminated infections \[[@pone.0237046.ref001]--[@pone.0237046.ref003]\]. *Candida albicans* is widely accepted as the most virulent species in the genus, and is the etiological agent in approximately 50%, 95%, and 80--90% of cases of nosocomial bloodstream *Candida* infections, oropharyngeal and vulvovaginal candidiasis, respectively \[[@pone.0237046.ref004]--[@pone.0237046.ref007]\].

*C*. *albicans* is a complex of three closely-related species, *C*. *albicans sensu stricto*, *C*. *dubliniensis*, and *C*. *africana* \[[@pone.0237046.ref006], [@pone.0237046.ref008]\]. *C*. *africana*, which was first isolated in Africa in 1995, was proposed as a new species within the *C*. *albicans* complex in 2001 \[[@pone.0237046.ref009], [@pone.0237046.ref010]\]. With a worldwide distribution, *C*. *africana* has been isolated from diverse clinical specimens (mucous membranes, cutaneous samples, specimens from the urinary and respiratory tracts, blood) and has been reported to cause a wide variety of human infections including vulvovaginal candidiasis, oral thrush, and blood stream infections. \[[@pone.0237046.ref011]--[@pone.0237046.ref015]\].

Unlike the other members of *C*. *albicans* complex, *C*. *africana* is unable to form chlamydospores and cannot assimilate glucosamine, N-acetylglucosamine, trehalose, or DL-lactate. However, in common with *C*. *albicans* and *C*. *dubliniensis* it has retained the capacity to produce germ-tubes. Moreover, molecular studies have demonstrated high levels of genetic relatedness between *C*. *africana* and *C*. *albicans* \[[@pone.0237046.ref016]--[@pone.0237046.ref018]\]. Thus, differentiation of *C*. *africana* from the other members of *C*. *albicans* complex using conventional identification techniques is difficult \[[@pone.0237046.ref019], [@pone.0237046.ref020]\].

Given these issues, molecular methods such as an end point PCR based on size polymorphism of the *hwp1* gene (*C*. *albicans*: 941bp, *C*. *dubliniensis*: 569 bp, and *C*. *africana*: 700 bp) have been designed to discriminate between *C*. *albicans*, *C*. *dubliniensis*, and *C*. *africana* \[[@pone.0237046.ref021]\]. Using such approaches, the prevalence of *C*. *africana* within the *C*. *albicans* complex has been reported to vary significantly from 0 to 8.4% depending on the geographic regions in which analyses were performed \[[@pone.0237046.ref011], [@pone.0237046.ref019], [@pone.0237046.ref022]--[@pone.0237046.ref024]\]. Furthermore, while some studies have suggested that the susceptibility profiles of *C*. *africana* to antifungal drugs are similar to those of *C*. *albicans* \[[@pone.0237046.ref025]\], others have reported different antifungal susceptibility patterns for these species \[[@pone.0237046.ref008], [@pone.0237046.ref026]\]. In light of the above discrepancies concerning *C*. *africana* prevalence and antifungal susceptibility, the present review and meta-analysis was designed to summarize all of the available data concerning this recent addition to the *C*. *albicans* species complex.

Methods {#sec002}
=======

Search strategy {#sec003}
---------------

Two independent researchers conducted bibliographic search in PubMed, Scopus, and Web of Science databases as well as in Google Scholar using keywords or phrases "*Candida africana*", "*C*. *africana*", "*Candida albicans* complex", "*Candida albicans* sibling species", and "*Candida albicans* cryptic species" and their combinations. Since *Candida africana* was first described as a novel species in 2001 \[[@pone.0237046.ref010]\], our search covered the literature published in the English language from 2001 to 21^st^ March 2020.

Study selection {#sec004}
---------------

Citations were included into EndNote software version X8, duplicates were deleted and the title and abstract of remaining citations were reviewed to exclude irrelevant articles. For the remaining citations, full texts were downloaded and evaluated. All English language articles with available full texts that reported data on antifungal susceptibility patterns of *Candida africana* and/or prevalence of *Candida africana* within the *Candida albicans* species complex using molecular methods met the inclusion criteria. Conference abstracts, review articles, and articles reporting data other than the susceptibility pattern and/or prevalence of *Candida africana* were excluded. The quality of the selected studies was checked using the STROBE checklist \[[@pone.0237046.ref027]\]. References cited in the eligible articles were also screened to guarantee the inclusion of all relevant studies.

Data extraction {#sec005}
---------------

Data including the name of the first author, publication year, country, number of *Candida albicans* complex isolates, number of identified *Candida africana* isolates, the source of *Candida africana* isolates, and the minimum inhibitory concentration (MIC) values of various drugs against *Candida africana* isolates were extracted into a pre-prepared excel file by two independent researchers. Corresponding authors of studies reporting only the summary data of antifungal susceptibility pattern such as MIC range, geometric mean (GM), and MIC~50~ were contacted via email for the raw data. In the case of no response, the summarized data of antifungal susceptibility patterns were excluded from the final analysis.

Data analysis {#sec006}
-------------

The pooled estimated prevalence of *C*. *africana* within the *C*. *albicans* complex was calculated using Stata software version 14. Variances and their confidence intervals were calculated using exact method. The pooled estimate was between 0 to 1. For studies reporting a prevalence of 0%, Freeman-Tukey double arcsine transformation was used to stabilize variances. Heterogeneity was determined using the I^2^ statistic which was calculated using the DerSimonian-Laird method. For quantification of heterogeneity, Cochrane Q test was used. In the presence of heterogeneity, random effect model provides better estimates \[[@pone.0237046.ref028], [@pone.0237046.ref029]\], accordingly, we used this model in calculations when heterogeneity was proved to exist. Subgroup analysis was done to define the prevalence of *C*. *africana* within the *C*. *albicans* complex in different countries and continents. The presence of publication bias was checked by using the funnel plot and the Begg\'s test. In the case of asymmetric funnel plot, Trim and Fill method was used to define the number of missing studies and the imputed estimated prevalence. To check for changes in prevalence over time, meta regression was conducted where the year of publication was set as the independent variable. In all calculations p-values \<0.05 were considered to be significant.

Results {#sec007}
=======

A summary of the results of the search strategy is depicted in [Fig 1](#pone.0237046.g001){ref-type="fig"}. The original bibliographic search identified 363 articles. An additional 3 articles were identified though examination of all of the literature cited in the retained articles (other sources, [Fig 1](#pone.0237046.g001){ref-type="fig"}). After de-duplication and exclusion of irrelevant citations based on the title and abstract, 73 articles were retained for full text evaluation. At this stage, 32 articles were excluded on the basis of the criteria listed in [Fig 1](#pone.0237046.g001){ref-type="fig"} and 41 articles were eligible to be included in the present study ([Table 1](#pone.0237046.t001){ref-type="table"}). Due to the presence of heterogeneity (I^2^ = 66.02%, 95% CI 44--77, *p*\<001), random-effect model was used. The pooled prevalence of *C*. *africana* within the *C*. *albicans* complex was 1.67% (95% CI 0.98--2.49) ([Fig 2](#pone.0237046.g002){ref-type="fig"}). Data on prevalence were available for 11 countries from 4 continents. Iran (3.02%, 95%CI 1.51--4.92) and Honduras (3.03%, 95% CI 0.83--10.39) had the highest values and Malaysia (0%) had the lowest reported prevalence. ([Table 2](#pone.0237046.t002){ref-type="table"}, [S1 Fig](#pone.0237046.s001){ref-type="supplementary-material"} and [S2 Fig](#pone.0237046.s002){ref-type="supplementary-material"}).

![The PRISMA flow diagram for selection of studies reporting data on intra-*Candida albicans* complex prevalence and/or antifungal susceptibility patterns of *Candida africana* from 2001 to March 2020.](pone.0237046.g001){#pone.0237046.g001}

![The forest plot of intra-*Candida albicans* complex prevalence of *Candida africana* based on the reported articles between 2001 to March 2020 (size of squares is representative of the relative weight of studies).](pone.0237046.g002){#pone.0237046.g002}

10.1371/journal.pone.0237046.t001

###### Characteristics of 41 studies reporting data on intra-*Candida albicans* complex prevalence and/or antifungal susceptibility pattern of *Candida africana* which were eligible to be included in the current systematic review and meta-analysis.
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  Reference                                         Year   Country          No. of *C*. *albicans* complex/*C*.*africana*   Source of isolates (N)             Data of antifungal drugs
  ------------------------------------------------- ------ ---------------- ----------------------------------------------- ---------------------------------- ----------------------------------------------------------------------
  Alonso-Vargas et al. \[[@pone.0237046.ref030]\]   2008   Spain            NA/1                                            Vagina (1)                         Flu, ITR, VRC, KTC, AmB, FLC
  Borman et al. \[[@pone.0237046.ref017]\]          2013   United Kingdom   826/15                                          Vagina (15)                        Flu, ITR, MCN, KTC, CLT, ECN, AmB, NYS
  Dieng et al. \[[@pone.0237046.ref031]\]           2012   Senegal          112/3                                           Vagina (3)                         NA
  Fakhim et al. \[[@pone.0237046.ref032]\]          2020   Iran             114/3                                           Vagina (3)                         Flu, ITR, VRC, AmB, FLC, CSP, ANF, MCF
  Farahyar et al. \[[@pone.0237046.ref033]\]        2020   Iran             100/3                                           Vagina (3)                         Flu, ITR
  Feng et al. \[[@pone.0237046.ref022]\]            2015   China            49/0                                            \-                                 NA
  Fontecha et al. \[[@pone.0237046.ref006]\]        2019   Honduras         66/2                                            Vagina (1), Urine (1)              NA
  Gil-Alonso et al. \[[@pone.0237046.ref008]\]      2015   Spain            NA/2                                            Vagina (1), Reference strain (1)   MCF
  Gil -Alonso et al. \[[@pone.0237046.ref034]\]     2015   Spain            NA/2                                            Vagina (1), Reference strain (1)   CSP, ANF, MCF
  Gil-Alonso et al. \[[@pone.0237046.ref026]\]      2016   Spain            NA/2                                            Vagina (1), Reference strain (1)   CSP
  Gil-Alonso et al. \[[@pone.0237046.ref035]\]      2019   Spain            NA/2                                            Vagina (1), Reference strain (1)   ANF
  Gumral et al. \[[@pone.0237046.ref023]\]          2011   Turkey           195/0                                           \-                                 NA
  Guzel et al. \[[@pone.0237046.ref036]\]           2013   Turkey           58/0                                                                               NA
  Hashemi et al. \[[@pone.0237046.ref037]\]         2019   Iran             44/2                                            Vagina (2)                         NA
  Hazirolana et al. \[[@pone.0237046.ref025]\]      2017   Turkey           376/3                                           Vagina (3)                         Flu, VRC, KTC, AmB, ANF, MCF
  Hu et al. \[[@pone.0237046.ref038]\]              2015   China            129/5                                           Balanitis (5)                      Flu, ITR, VRC, PSC, AmB, FLC, CSP, MCF
  Kardos et al. \[[@pone.0237046.ref039]\]          2017   Hungary          NA/2                                            Vagina (1), Reference strain (1)   MCF
  Khedri et al. \[[@pone.0237046.ref013]\]          2018   Iran             74/4                                            Oral lesions (4)                   Flu, ITR, VRC, AmB, CSP
  Kova´cs et al. \[[@pone.0237046.ref039]\]         2017   Hungary          NA/2                                            Vagina (1), Reference strain (1)   MCF
  Lortholary et al. \[[@pone.0237046.ref040]\]      2007   France           NA/3                                            NA                                 Flu, VRC, PSC
  Majdabadi et al. \[[@pone.0237046.ref041]\]       2018   Iran             40/2                                            Vagina (2)                         Flu, ITR, AmB
  Mucci et al. \[[@pone.0237046.ref005]\]           2017   Argentina        57/0                                                                               NA
  Naeimi et al. \[[@pone.0237046.ref019]\]          2018   Iran             119/10                                          Vagina (10)                        Flu
  Ngouana et al. \[[@pone.0237046.ref020]\]         2014   Cameroon         115/2                                           Vagina (2)                         Flu, ITR, KTC, AmB
  Ngouana et al. \[[@pone.0237046.ref042]\]         2019   Cameroon         115/2                                           Vagina (2)                         NA
  Nnadi et al. \[[@pone.0237046.ref043]\]           2012   Italy            84/2                                            Vagina (2)                         Flu, VRC, PSC, AmB, CSP, KTC, ITR, FLC
  Pakshir et al. \[[@pone.0237046.ref044]\]         2017   Iran             110/0                                           \-                                 NA
  Rezazadeh et al. \[[@pone.0237046.ref045]\]       2016   Iran             67/4                                            Vagina (4)                         NA
  Rezazadeh et al. \[[@pone.0237046.ref045]\]       2016   Iran             NA/4                                            NA                                 Flu, ITR, VRC, PSC, AmB, CSP
  Romeo et al. \[[@pone.0237046.ref046]\]           2009   Italy            376/27                                          Vagina (27)                        NA
  Romeo et al. \[[@pone.0237046.ref046]\]           2009   Italy            134/1                                           Vagina (1)                         NA
  Scordino et al. \[[@pone.0237046.ref001]\]        2019   Italy            21/0                                            \-                                 NA
  Shan et al. \[[@pone.0237046.ref003]\]            2014   China            1014/15                                         Vagina (15)                        Flu, ITR, NYS, MCN, CLT
  Sharifynia et al. \[[@pone.0237046.ref014]\]      2015   Iran             83/1                                            Lung (1)                           Flu, ITR, AmB, CSP
  Sharma et al. \[[@pone.0237046.ref016]\]          2014   India            283/4                                           Vagina (4)                         Flu, ITR, MCN, VRC, KTC, CLT, PSC, ISC, AmB, FLC, CSP, ANF, MCF, TRB
  Shokohi et al. \[[@pone.0237046.ref047]\]         2018   Iran             47/1                                            Skin (1)                           NA
  Solimani et al. \[[@pone.0237046.ref024]\]        2014   Iran             35/0                                            \-                                 NA
  Theill et al. \[[@pone.0237046.ref002]\]          2016   Argentina        287/1                                           Vagina (1)                         Flu, ITR, VRC, CLT, AmB, TRB, NYS
  Yazdanpanah et al. \[[@pone.0237046.ref011]\]     2014   Malaysia         98/0                                            \-                                 NA
  Yazdanparast et al. \[[@pone.0237046.ref048]\]    2015   Iran             114/5                                           Vagina (5)                         Flu, ITR, VRC, PSC, AmB, CSP, ANF, MCF
  Zhu et al. \[[@pone.0237046.ref012]\]             2019   China            NA/43                                           Vagina (43)                        Flu, ITR, MCN, VRC, CLT, BTC, TRC

Abbreviations: NA: not available, Flu: fluconazole, ITR: itraconazole, VRC: voriconazole, KTC: ketoconazole, AmB: amphotericin B, FLC: 5-fluorocytosine, MCN: miconazole, CLT: clotrimazole, ECN: econazole, NYS: nystatin, CSP: caspofungin, ANF: anidulafungin, MCF: micafungin, PSC: posaconazole, TRB: terbinafine, ISC: isavuconazole, BTC: butoconazole, TRC: terconazole

10.1371/journal.pone.0237046.t002

###### The pooled intra-*Candida albicans* complex prevalence of *Candida africana* in different countries and continents based on the reported studies between 2001 to March 2020.
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  Continent        Country              Prevalence (%) (95% confidence interval)
  ---------------- -------------------- ------------------------------------------
  Africa           Cameroon             1.74 (0.65--4.54)
  Senegal          2.68 (0.87--7.98)    
  Overall          2.09 (1--4.32)       
  America          Argentina            0.11 (0.00--1.04)
  Honduras         3.03 (0.83--10.39)   
  Overall          0.51 (0.00--2.46)    
  Asia             China                1.50 (0.22--3.57)
  India            1.41 (0.55--3.58)    
  Iran             3.02 (1.51--4.92)    
  Malaysia         0.00 (0.00--3.77)    
  Turkey           0.22 (0.00--0.91)    
  Overall          1.66 (0.81--2.73)    
  Europe           Italy                2.33 (0.04--6.79)
  United Kingdom   1.82 (1.10--2.97)    
  Overall          2.17 (0.29--5.25)    

As shown in [Fig 3](#pone.0237046.g003){ref-type="fig"}, the funnel plot was broadly symmetrical, suggesting the absence of publication bias. This finding was confirmed using Begg\'s test (Z = 1.26, *p* = 0.215). In meta-regression analysis, no evidence for significant change in the prevalence of *C*. *africana* over time was found (Coefficient = -0.0013, SE = 0.0052, *p* = 0.802) ([S3 Fig](#pone.0237046.s003){ref-type="supplementary-material"}).

![The funnel plot of available studies reporting data on intra-*Candida albicans* complex prevalence of *Candida africana* between 2001 to March 2020 (each circle is representative of one study).](pone.0237046.g003){#pone.0237046.g003}

Information on isolation source was available for a total of 167 isolates. Although the vast majority of isolates were from the female genital tract (vagina; n = 155, 92.81%), there were also isolates from patients with balanitis (n = 5, 2.99%), oral lesions (n = 4, 2.39%), and isolates from respiratory, urine, and skin samples (1 isolate each, 0.6%).

MIC values were available for *C*. *africana* isolates and 16 antifungal drugs including azoles, echinocandins, polyenes, allylamine, and 5-flucytosine. As shown in [Table 3](#pone.0237046.t003){ref-type="table"}, the MIC ranges, MIC~50~ and MIC~90~ and geometric mean values were generally low.

10.1371/journal.pone.0237046.t003

###### The summary of all data reporting antifungal susceptibility patterns of *Candida africana* during 2001 to March 2020 (studies without raw data of minimum inhibitory concentrations are not included).
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  Antifungal drug   No. of isolates with available data   Minimum inhibitory concentration (MIC) values (μg/mL)                   
  ----------------- ------------------------------------- ------------------------------------------------------- ------- ------- -------
  Fluconazole       53                                    0.063--1                                                0.125   0.5     0.13
  Itraconazole      43                                    0.016--0.25                                             0.031   0.125   0.031
  Voriconazole      30                                    0.008--0.25                                             0.016   0.25    0.022
  Ketoconazole      23                                    0.008--2                                                0.063   0.063   0.04
  Posaconazole      21                                    0.008--0.031                                            0.016   0.016   0.013
  Miconazole        18                                    0.016--0.063                                            0.063   0.063   0.046
  Clotrimazole      18                                    0.016--0.25                                             0.063   0.063   0.048
  Econazole         10                                    0.063--0.063                                            0.063   0.063   0.063
  Isavuconazole     4                                     0.016--0.016                                            0.016   0.016   \-
  Caspofungin       27                                    0.008--0.5                                              0.031   0.25    0.040
  Micafungin        22                                    0.008--0.125                                            0.016   0.063   0.018
  Anidulafungin     13                                    0.008--0.063                                            0.016   0.031   0.016
  Amphotericin B    35                                    0.016--8                                                0.125   0.5     0.113
  Nystatin          15                                    0.031--2                                                1       2       0.758
  5-flucytosine     6                                     0.016--0.125                                            0.063   0.125   \-
  Terbinafine       5                                     1--2                                                    2       2       \-

Discussion {#sec008}
==========

*C*. *africana*, a member of *C*. *albicans* species complex, is genetically and phenotypically closely related to *C*. *albicans*. The pathogenicity of *C*. *africana* and its impact on the health of humans is poorly understood. Moreover, the global prevalence and antifungal susceptibility profiles of this species are not clearly defined \[[@pone.0237046.ref016], [@pone.0237046.ref018], [@pone.0237046.ref030]\]. In this study we tried to provide an overview of the available data published to date on both of these aspects of *C*. *africana* epidemiology/biology.

*C*. *africana* appears to be globally distributed, with an intra-*C*. *albicans* complex prevalence that varies in different regions and countries \[[@pone.0237046.ref016], [@pone.0237046.ref031], [@pone.0237046.ref043]\]. To date, data concerning prevalence are available for 11 countries from 4 continents (Africa, America, Asia, and Europe), with a pooled intra-complex prevalence of 1.67% (95% CI 0.98--2.49). Based on the available literature, Malaysia (0.0%; 95% CI 0.0--3.77) has the lowest prevalence. Iran (3.02%; 95% CI 1.51--4.92) and Honduras (3.03%; 95% CI 0.83--10.39) have the highest prevalence. However, since prevalence in Iran was drawn from 12 different studies, it is likely to be a more reliable estimate than the prevalence reported for Honduras, which was based on a single study. Variation in prevalence could be seen between and across continents. For instance, although Iran has the highest prevalence, the prevalence of *C*. *africana* in a neighboring country, Turkey, is dramatically lower (0.22%; 95% CI 0.0--0.91). It is unclear whether this difference in relative prevalence is the result of an insufficient number of studies in Turkey, genuine local geographical variation, or a combination of both. It is also worth mentioning that the prevalence values reported in the current study are estimated with limited numbers of studies from each country. Data are also lacking for the majority of countries. Thus, the present view might change if there were more studies internationally that addressed the prevalence of *C*. *africana*.

The intra-complex prevalence of *C*. *africana* appears to be constant over time. In recent decades, the prevalence of non-*albicans Candida* species has increased \[[@pone.0237046.ref049], [@pone.0237046.ref050]\] and there are reports describing species other than *C*. *albicans* as being the most common etiologic agents of infection locally \[[@pone.0237046.ref051]--[@pone.0237046.ref053]\]. However, it seems that a similar scenario has not been occurring within the *C*. *albicans* species complex since the meta-regression analysis of our data indicates that there is no significant change in the intra-complex prevalence of *C*. *africana* with the passage of time. However, once again there are caveats to this suggestion. First, it is based on data from a limited number of countries. Moreover, the power of meta-regression analyses is low especially when the number of studies included is low, which is the case in the present study.

Female genital specimens are the most common source of isolation of *C*. *africana*. Of 167 *C*. *africana* isolates with available data, the majority (n = 155, 92.81%) were from the vagina. Vulvovaginal candidiasis due to *C*. *africana* has been reported in various countries \[[@pone.0237046.ref032]\]. This species was also isolated from cases of balanitis (n = 5, 2.99%) and oral lesions (n = 4, 2.39%), and from respiratory, urine, and skin samples (each 1 isolate, 0.6%), all of which could conceivably become contaminated with vaginal flora or pathogens. The apparent preponderance of *C*. *africana* for the female genital tract highlights the need for appropriate methods for discrimination of *C*. *africana* from *C*. *albicans* complex isolates, especially for vaginal specimens.

Data on antifungal susceptibility of *C*. *africana* to 16 antifungal drugs are available in the published literature ([Table 3](#pone.0237046.t003){ref-type="table"}). It should be highlighted that the data presented in [Table 3](#pone.0237046.t003){ref-type="table"} are limited to articles in which detailed results of antifungal susceptibility testing are provided. Other articles that have reported their results as the number of resistant/susceptible isolates or as geometric mean and MIC range (and not the raw MICs) could not be included in [Table 3](#pone.0237046.t003){ref-type="table"}. Similar patterns of susceptibility to various antifungal drugs has been reported for *C*. *africana* and *C*. *albicans* \[[@pone.0237046.ref025]\], while other studies have noted that *C*. *africana* exhibits a different susceptibility pattern to *C*. *albicans* \[[@pone.0237046.ref008], [@pone.0237046.ref026]\]. Since there are no specified clinical breakpoints or epidemiological cut-off values (ECVs) for antifungal drugs against *C*. *africana*, the interpretation of MICs as susceptible/resistant or wild-type/non wild-type is potentially controversial. However, there are reports in which isolates of *C*. *africana* have been categorized as resistant to itraconazole, 5-flucytosine, terbinafine, fluconazole, and clotrimazole \[[@pone.0237046.ref028], [@pone.0237046.ref033], [@pone.0237046.ref054]\]. By applying the clinical breakpoints for *C*. *albicans* (CLSI M60) \[[@pone.0237046.ref055]\], the species most closely related to *C*. *africana*, it could be inferred that almost all isolates of *C*. *africana* with available MICs for fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin are susceptible to these antifungal drugs. For itraconazole, in contrast to CLSI (M60 supplement) \[[@pone.0237046.ref055]\] which no longer proposes breakpoints for *Candida* species, the European Committee on Antimicrobial Susceptibility Testing recently published new breakpoints for itraconazole against *C*. *albicans* and *C*. *dubliniensis* \[[@pone.0237046.ref029]\]. Using those breakpoints (\>0.06 μg/mL = resistance) 12 out of 43 (27.91%) *C*. *africana* isolates with available data would be itraconazole-resistant. Further studies will be required to generate MIC data for sufficient numbers of isolates of *C*. *africana* to allow the establishment of robust species-specific ECVs and clinical breakpoints for this species.

Conclusion {#sec009}
==========

*C*. *africana* is a minor species within the *C*. *albicans* complex with a pooled prevalence of 1.67%. Reports of this species are available from a limited number of countries and further investigations are required internationally to fully address its global distribution. The vagina is the most common human source of *C*. *africana* and based on clinical breakpoints established for the related *C*. *albicans*, this species can be inferred to be generally susceptible to most currently available antifungal drugs.

Supporting information {#sec010}
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###### The forest plot of intra-*Candida albicans* complex prevalence of *Candida africana* in different countries based on the reported articles between 2001 to 2020 (size of squares is representative of the relative weight of studies).
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###### The forest plot of intra-*Candida albicans* complex prevalence of *Candida africana* in different continents based on the reported articles between 2001 to 2020 (size of squares is representative of the relative weight of studies).

(TIF)
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###### The meta-regression of intra-*Candida albicans* complex prevalence of *Candida africana* with the time (size of circles is representative of the relative weight of studies; studies with a prevalence of 0% are not shown).

(TIF)
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Joy Sturtevant

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Additional Editor Comments (if provided):

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This article provides a metadata analysis of the less known fungal pathogen C. africana. The paper suffers from a few issues that can be addressed as follows:

The paper needs to be reviewed by a native English speaker as their are many grammatical and wording mistakes. An example of these area as follows:

Sentence structures and English errors:

Line 34-35: sentence should be revised.

Line 62-63: sentence needs to be corrected and susceptibility \"to drugs\" should be added.

Line 134: \"values\" not vales.

Line 150: \"is\" should be added between \"It\" and \"worthy\".

Line 155: \"this estimated values\" should be \"this estimated value\".

Line 35: Change "which suggesting" to "which suggest".

Lines 35 -- 37: This sentence should be reformulated since it is not clear: "C. africana is a minor species within the C. albicans complex with geographical variation in prevalence and high susceptibility to antifungal drugs".

Line 44: Change "for infection in human" to "for human infections".

Line 61: Change "vary" to "varies".

Line 78: Change "pattern" to "patterns".

Line 102: Change "remained" to "were retained".

Line 103: Change "by reasons (fig. 1)" to "according to the reasons mentioned in fig. 1".

Line 152: Change "if there be more studies" to "if there were more studies".

Line 157: Change "over the time" to "over time".

Line 159: Change "agent" to "agents".

Line 168: Change "such as cases of" to "such as in cases of".

Line 187: Change "from limited number" to "from a limited number

As far as content please find the below comments that need to be addressed. Especially the issue of antifungal MICs and breakpoints, and which guidelines to use:

1\. Version of \"Comprehensive Meta-Analysis software\" used should be indicated along with the version of any other program or software used.

2\. Not all abbreviations are included in the \"abbreviation\" section under Table 1 such as AmB.

3\. Funnel Plot shows only 28 circles while it should include 41 circles resembling all included studies. Please explain this discrepancy.

4\. What are the \"other sources\" mentioned in Figure 1?

5\. It would be better to mention some molecular methods in line 59.

6\. Titles of all tables and figures should be modified to include legends or symbols, and all needed info so that one can understand them without referring to the text.

7\. In the discussion, it is stated that C. africana is susceptible to most antifungal drugs \"fluconazole, itraconazole, voriconazole, anidulafungin, caspofungin, micafungin and flucytosine\". Other studies show that it is sensitive to conventional antifungals but rather resistant to voriconazole, flucytosine, and terbinafine (Naeimi et al., Journal of Medical Microbiology 2018): This should be addressed in the discussion as it is contradicting info.

The discussion could be slightly improved by not comparing the MICs of itraconazole and flucytosine in Candida africana to those of Candida albicans according to the CLSI M60 guidelines because in these guidelines there is no proof of correct MIC breakpoints for these antifungals with Candida albicans. Moreover, it is suggested in the CLSI M60 guidelines to not take into consideration MIC breakpoints for these antifungals in Candida albicans from previous guidelines where minimal clinical data were used to establish them. For itraconazole, the analysis could be made by using as reference the EUCAST 2018 guidelines.

Do not compare the Candida albicans and Candida africana MICs for flucytosine since no breakpoints for this antifungal exist in both the CLSI M60 and EUCAST 2018 guidelines.

Reviewer \#2: I will focus on methods and reporting

Major

1\) reading the abstract it was not clear to me what the antifungal aim was - the prevalence aspect was clear

2\) similarly at the end of the introduction there is a mention to the \"susceptibility pattern\" of the species. this is not clear enough the aims needs to be made much more clear and specific at the end of that section.

3\) I don\'t see how publication bias tests are relevant when prevalence is investigated. there is no effect size and as far as I know there is no equivalent test. can the authors expand on this?

4\) Meta-analyses of proportions are a bit more complicated since transformations are needed to account for the 0 and 100% limits. Step 1: transformation; step 2: meta-analysis method using standard approach (i.e. inverse variance DerSimonian-Laird); step 3: back-transformation to percentages and plotting. One approach is logit transformation, which is explained in a different context here: <http://www.bmj.com/content/352/bmj.i1114>. However, a double arcsine transformation is the norm (<http://jech.bmj.com/content/early/2013/08/20/jech-2013-203104>). Is that what the software you use does? either way, can you clarify please?

5\) Meta-regression is a stab in the dark usually and is underpowered to detect anything but massive associations (effectively a regression with X observations, where X is the number of available studies). You should discuss this as a major limitation. Even with 60 or 80 studies, it can provide little insight.

6\) Avoid fixed effect models since they under-perform in the presence of ANY heterogeneity. Random-effects (RE) models are more conservative and provide better estimates with wider confidence intervals: <http://www.ncbi.nlm.nih.gov/pubmed/11252006> and <http://www.ncbi.nlm.nih.gov/pubmed/21148194> . What does the arbitrary 50% cut-off point add? Why is 49% fine and 51% an issue? My point is that a RE model will work better, in the presence of 5% heterogeneity, compared to a FE model!

7\) Report the confidence intervals for I\^2 (calculated using heterogi or metaan in Stata) as argued in <http://www.ncbi.nlm.nih.gov/pubmed/17974687>. A simple formula exists in the seminal 2002 Higgins paper that proposed I\^2.

Minor

1\) why the 2001 start for the literature search?

2\) some language corrections are needed.

3\) there is a mention to \"intra-complex\" prevalence in the abstract. I don\'t know what this is and uncless the authors are very confident about the term and it\'s just not my area of expertise (which is meta-analysis methods) I\'d ask them to revise it.

4\) clarify that in the regression the independent variable is year.

5\) How was the random-effect model implemented, i.e. how was heterogeneity estimated? There are numerous ways to do so. Did they use the standard DerSimonian-Laird method? If so, please state so. Also there are better performing methods, for example please see <https://www.ncbi.nlm.nih.gov/pubmed/28815652> (or <http://www.ncbi.nlm.nih.gov/pubmed/23922860>) and the metaan command in Stata where these are implemented (<https://www.stata-journal.com/article.html?article=st0201>).

6\) Cochran Q (i.e. chi-square) is notoriously underpowered to detect heterogeneity, especially for small meta-analyses <http://www.ncbi.nlm.nih.gov/pubmed/9595615>. I would not use

7\) the quality of the forest plot is poor. for example there is no negative prevalence, edit the scale.

8\) High heterogeneity estimates according to some researchers mean studies should not be meta-analysed. However, I disagree with that assessment for numerous methodological reasons. First heterogeneity is not study size independent: smaller meta-analyses are more often homogeneous and larger studies are heterogeneous (for both methodological and practical reasons). So according to this mantra we will be filtering out the most valuable analyses, the ones that involve many studies, over the much smaller ones. In addition, random effects models can model that heterogeneity and account for it. Finally, large heterogeneity is the norm and it\'s great if it has been picked up and can be incorporated in the model. It is much more problematic when the underlying heterogeneity is not picked up and studies are \"safely\" combined under a homogeneity assumption. In other words, small meta-analyses of "homogeneous" studies are much more problematic than large "heterogeneous" ones as evidenced in this <http://www.ncbi.nlm.nih.gov/pubmed/23922860>. In smaller meta-analyses existing heterogeneity is just not picked up well enough. The uncertainty of the estimate becomes obvious if the CIs for I\^2 are reported, as argued in <http://www.ncbi.nlm.nih.gov/pubmed/17974687>.

Reviewer \#3: The manuscript \[PONE-D-20-13736\] entitled "Distribution, antifungal susceptibility pattern and intra-Candida albicans species complex prevalence of Candida africana: A systematic review and meta-analysis" reviewed and discussed a general view about the prevalence and susceptibility pattern of Candida albicans species complex.

The title, aim and body of manuscript are not concise and coherent. Moreover, there were a surprisingly high number of spelling mistakes considering this standard of writing. Manuscript needs to be a major revision of English editing, preferably by a native speaker/editor.

Authors mentioned

Due to the limited knowledge concerning the prevalence and antifungal susceptibility pattern of this species, a comprehensive study is needed in this regard.

Major comments, manuscript is a superficial paper and has poorly prepared "head and tail". Based on ref. 30, Candida africana Vulvovaginitis: Prevalence and Geographical Distribution. J Mycol Med. 2020:100966, recently has been already published in this particular region. What is new in this particular paper?

As presented, it does not merit acceptance. It is more suitable for a local journal. It is agreed that this could be a useful contribution to the literature but not just yet-there simply is not enough data to be of any practical use.

Comments to Author:

Interpretation and conclusions: derived from the data.

References: up to date and relevant.

Abstract reflects the content of the paper

Limited number of terms (i.e., key words) used to conduct searches was presented, what may lead to an underestimate of the general picture of the evidence base available for analysis. The number of terms used to conduct searches, including MeSH terms and free terms should be developed.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237046.r002
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PONE-D-20-13736

Reviewers\' comments:

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Partly

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

Response: We are somewhat confused by this comment raised by reviewer \#3. All of the data used in this study are presented in full in the accompanying text, tables, figures and supplementary files. The statistical reviewer and reviewer \#1 also confirm that all the data are available.

If reviewer \#3 means that our study did not capture all the relevant articles and data because our search strategy is restricted, our response to this concern is given in the section dedicated to the specific issues raised by reviewer \#3.

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Response: The manuscript has now been fully revised by a native English speaker to improve its quality.

5\. Review Comments to the Author

Reviewer \#1:

This article provides a metadata analysis of the less known fungal pathogen C. africana. The paper suffers from a few issues that can be addressed as follows:

The paper needs to be reviewed by a native English speaker as there are many grammatical and wording mistakes.

Response: Thank you for your detailed review and for highlighting errors in writing. Based on your comment, the manuscript was referred to native English speaker who is active in the field of Candida research. He has extensively revised the text throughout, and is now included as a co-author.

An example of these area as follows:

Sentence structures and English errors:

Line 34-35: sentence should be revised.

Response: This sentence has been modified in the revised version.

Line 62-63: sentence needs to be corrected and susceptibility \"to drugs\" should be added.

Response: Thank you for your suggestion. This was revised in line with your comments.

Line 134: \"values\" not vales.

Line 150: \"is\" should be added between \"It\" and \"worthy\".

Line 155: \"this estimated values\" should be \"this estimated value\".

Line 35: Change "which suggesting" to "which suggest".

Lines 35 -- 37: This sentence should be reformulated since it is not clear: "C. africana is a minor species within the C. albicans complex with geographical variation in prevalence and high susceptibility to antifungal drugs".

Response: Thank you for pointing out this issue. This was revised to improve its clarity.

Line 44: Change "for infection in human" to "for human infections".

Line 61: Change "vary" to "varies".

Line 78: Change "pattern" to "patterns".

Line 102: Change "remained" to "were retained".

Line 103: Change "by reasons (fig. 1)" to "according to the reasons mentioned in fig. 1".

Line 152: Change "if there be more studies" to "if there were more studies".

Line 157: Change "over the time" to "over time".

Line 159: Change "agent" to "agents".

Line 168: Change "such as cases of" to "such as in cases of".

Line 187: Change "from limited number" to "from a limited number

Response: Thank you for your suggestions. All the above errors have been corrected in the revised version of the manuscript, and additional textual changes have been introduced to improve readability.

As far as content please find the below comments that need to be addressed. Especially the issue of antifungal MICs and breakpoints, and which guidelines to use:

1\. Version of \"Comprehensive Meta-Analysis software\" used should be indicated along with the version of any other program or software used.

Response: Thank you for your suggestion. Based on the comments of reviewer \#2, we re-analyzed all of the data using Stata software. Versions of both Stata and EndNote programs were added.

2\. Not all abbreviations are included in the \"abbreviation\" section under Table 1 such as AmB.

Response: We apologize for this oversight in the original version. All the abbreviations used in Table 1 are now included in the "abbreviation" section under Table 1.

3\. Funnel Plot shows only 28 circles while it should include 41 circles resembling all included studies. Please explain this discrepancy.

Response: As indicated in Table 1, only a proportion of the 41 articles present data of prevalence. Some articles only included data on antifungal susceptibility testing, and other studies were performed on reference strains. Those studies could not be included in the funnel plot which presents data for prevalence. Because of this, the number of articles in funnel plot is less than the total number of included studies. Please note also that the number of studies presented in funnel plot is actually 31, with several circles almost exactly overlaying other data points.

4\. What are the \"other sources\" mentioned in Figure 1?

Response: The database search returned 363 records. After removing duplicate and irrelevant articles, the full texts of the remaining articles were selected for data extraction. The complete reference lists of all retained articles were also checked to guarantee that we had not missed any articles. Using this procedure we identified three additional records. This has now been clarified at the beginning of the results section.

5\. It would be better to mention some molecular methods in line 59.

Response: Thank you for your suggestion. The relevant section has been amended.

6\. Titles of all tables and figures should be modified to include legends or symbols, and all needed info so that one can understand them without referring to the text.

Response: Table titles and figure legends have been modified and more information provided so that they are understandable independently of the main text.

7\. In the discussion, it is stated that C. africana is susceptible to most antifungal drugs \"fluconazole, itraconazole, voriconazole, anidulafungin, caspofungin, micafungin and flucytosine\". Other studies show that it is sensitive to conventional antifungals but rather resistant to voriconazole, flucytosine, and terbinafine (Naeimi et al., Journal of Medical Microbiology 2018): This should be addressed in the discussion as it is contradicting info.

Response: Thank you for your comment. The relevant section of the discussion has been revised and specific mention of this conflicting report has been made.

8\. The discussion could be slightly improved by not comparing the MICs of itraconazole and flucytosine in Candida africana to those of Candida albicans according to the CLSI M60 guidelines because in these guidelines there is no proof of correct MIC breakpoints for these antifungals with Candida albicans. Moreover, it is suggested in the CLSI M60 guidelines to not take into consideration MIC breakpoints for these antifungals in Candida albicans from previous guidelines where minimal clinical data were used to establish them. For itraconazole, the analysis could be made by using as reference the EUCAST 2018 guidelines. Do not compare the Candida albicans and Candida africana MICs for flucytosine since no breakpoints for this antifungal exist in both the CLSI M60 and EUCAST 2018 guidelines.

Response: We appreciate this suggestion for improving our work. This part of the discussion has been extensively modified in the revised version and your comments have been addressed.

Reviewer \#2:

I will focus on methods and reporting

Comment to reviewer: Dear reviewer, we really appreciate your detailed review and we would like to thank you for all of your comments which have helped us to significantly improve the present work. Based on your comments and suggestions, and because the previous software we have used had limitations that meant that we were not able to edit the plots or export them in better formats, we have re-analyzed the entire dataset using Stata software. Because the estimated prevalence values obtained by Stata were slightly different from those produced using the previous software, we checked a third software package which confirmed the results obtained with Stata and indicated that our previous results were slightly over-estimated. All of the prevalence values in the revised manuscript have been corrected, and are now based on the results obtained using Stata.

Major

1\) reading the abstract it was not clear to me what the antifungal aim was - the prevalence aspect was clear

Response: We apologize that this aspect of the original manuscript was not clear. We have now clarified this issue in both the abstract and the introduction. Effectively, a limited number of previous publications had offered conflicting messages regarding the antifungal susceptibility profiles of C. africana as a species, with several reports suggesting that it is likely to be susceptible to most currently employed antifungal drugs, but a least one report suggesting elevated MICs (and possible resistance) to some drugs. Thus, a secondary aim of the current study was to compile all of the available data regarding the susceptibility patterns of this fungus (Table 3) in order to provide a composite picture regarding the minimum inhibitory concentrations of antifungal drugs against this species. We hope that such data will be of use to the intended audience of this article (mycologists and microbiologists).

2\) similarly at the end of the introduction there is a mention to the \"susceptibility pattern\" of the species. this is not clear enough the aims needs to be made much more clear and specific at the end of that section.

Response: Once again, we thank the reviewer for highlighting the lack of clarity in the original manuscript. The offending section has been substantially revised (see also response to point 1 above).

3\) I don\'t see how publication bias tests are relevant when prevalence is investigated. there is no effect size and as far as I know there is no equivalent test. can the authors expand on this?

Response: Thank you for raising this potential concern. Based on consultations with experts in epidemiology and biostatistics, including in prevalence studies, we believe that publication bias might exist. For example, if the expected prevalence of a variable in a population is 20% but the result obtained in a given study is much different (for instance 2%), this study has a lower chance of being accepted for publication. We believe that this bias is likely to be more extreme regarding the topic of our article. Any study that reported a prevalence of 0% for Candida africana (ie failed to detect any occurences), has a very low chance of being accepted for publication, especially in recent years, as it is likely to be judged as "adding nothing useful to the literature". Conversely, studies that report C. africana isolates in a particular setting, especially if the reports are accompanied by additional analyses such as antifungal susceptibility testing, genotyping, determining enzymatic activities on different substances etc. will be deemed to generate new and interesting data in addition to a prevalence. Accordingly, in the latter situation, there is a significantly higher chance of this type of study being accepted for publication.

4\) Meta-analyses of proportions are a bit more complicated since transformations are needed to account for the 0 and 100% limits. Step 1: transformation; step 2: meta-analysis method using standard approach (i.e. inverse variance DerSimonian-Laird); step 3: back-transformation to percentages and plotting. One approach is logit transformation, which is explained in a different context here: <http://www.bmj.com/content/352/bmj.i1114>. However, a double arcsine transformation is the norm (<http://jech.bmj.com/content/early/2013/08/20/jech-2013-203104>). Is that what the software you use does? either way, can you clarify please?

Response: As discussed above, the software we used in the previous version of this article, although user-friendly, had several limitations. Based on your other comments, the meta-analysis was repeated using metaprop package in Stata software. Variances and their confidence intervals were calculated using exact method. The pooled estimate was from 0 to 1. For studies reporting a prevalence of 0%, Freeman-Tukey Double Arcsine Transformation was used to stabilize the variance.

These data have now been added to the manuscript, and the methods section has been amended to incorporate these changes in methodologies.

5\) Meta-regression is a stab in the dark usually and is underpowered to detect anything but massive associations (effectively a regression with X observations, where X is the number of available studies). You should discuss this as a major limitation. Even with 60 or 80 studies, it can provide little insight.

Response: This concern has now been discussed as a potential significant limitation in the Discussion section of the revised manuscript.

6\) Avoid fixed effect models since they under-perform in the presence of ANY heterogeneity. Random-effects (RE) models are more conservative and provide better estimates with wider confidence intervals: <http://www.ncbi.nlm.nih.gov/pubmed/11252006> and <http://www.ncbi.nlm.nih.gov/pubmed/21148194> . What does the arbitrary 50% cut-off point add? Why is 49% fine and 51% an issue? My point is that a RE model will work better, in the presence of 5% heterogeneity, compared to a FE model!

Response: Thank you for your invaluable comment. We re-analyzed the data using random-effect in Stata software. Furthermore, using the references you mentioned, we have clarified that in the presence of heterogeneity, random effect was used because in this situation it provides better estimates.

7\) Report the confidence intervals for I\^2 (calculated using heterogi or metaan in Stata) as argued in <http://www.ncbi.nlm.nih.gov/pubmed/17974687>. A simple formula exists in the seminal 2002 Higgins paper that proposed I\^2.

Reference: Thank you for your comment. The confidence interval for I\^2 was calculated and has been added to the manuscript.

Minor

1\) why the 2001 start for the literature search?

Response: The literature search was started from 2001 because Candida africana, the species we have focused on, was officially described in 2001 (Mycoses. 2001;44(11-12):437-445).This point has now been made in the revised manuscript.

2\) some language corrections are needed.

Response: The manuscript was revised by a native English speaker. We hope that the English language usage is now much improved.

3\) there is a mention to \"intra-complex\" prevalence in the abstract. I don\'t know what this is and uncless the authors are very confident about the term and it\'s just not my area of expertise (which is meta-analysis methods) I\'d ask them to revise it.

Response: Thank you for your comment. Candida africana, the organism which we have focused on, is a member of a complex consisting of several closely-related species, coined the Candida albicans species complex. Thus, when we report a prevalence for Candida africana within this complex, it is the "intra-Candida albicans complex prevalence of Candida africana" ie. we are measuring the "prevalence/proportion of Candida africana within the Candida albicans species complex". Based on your comment, all "intra-complex(s)" comments used in manuscript have been changed to read "intra-Candida albicans species complex" for clarity and consistency. We did also consult with an expert in epidemiology who advised that it is scientifically correct to use "intra-Candida albicans complex prevalence of Candida africana" in this context.

4\) clarify that in the regression the independent variable is year.

Response: Thank you for your comment. This has been clarified in the revised manuscript.

5\) How was the random-effect model implemented, i.e. how was heterogeneity estimated? There are numerous ways to do so. Did they use the standard DerSimonian-Laird method? If so, please state so. Also there are better performing methods, for example please see <https://www.ncbi.nlm.nih.gov/pubmed/28815652> (or <http://www.ncbi.nlm.nih.gov/pubmed/23922860>) and the metaan command in Stata where these are implemented (<https://www.stata-journal.com/article.html?article=st0201>).

Response: The heterogeneity was determined using I\^2 statistic. Based on your comment (Major 6, above) and our response, in the presence of heterogeneity, random-effect model was used. I\^2 was calculated using the standard DerSimonian-Laird method. These issues are clarified in the revised manuscript.

6\) Cochran Q (i.e. chi-square) is notoriously underpowered to detect heterogeneity, especially for small meta-analyses <http://www.ncbi.nlm.nih.gov/pubmed/9595615>. I would not use

Response: We agree with your comment. As you mentioned, Cochran Q (i.e. chi-square) has a low power for estimation of heterogeneity. However, it should be highlighted that we used this method for quantification of heterogeneity. This has been clarified in the section "Methods".

7\) the quality of the forest plot is poor. for example there is no negative prevalence, edit the scale.

Response: We agree with your comment. This was another issue that stemmed from the previous software we used in the original version of the manuscript. In response to your previous comments we have re-analyzed all of the data using Stata. As a result, we realized that the original prevalence values calculated using the previous software are indeed over-estimated. Accordingly, all the results are now revised. To ensure the accuracy of the new results, we also analyzed the data using a third software (medcalc) and the results confirmed those obtained with Stata. The manuscript has been modified throughout to capture these changes.

8\) High heterogeneity estimates according to some researchers mean studies should not be meta-analysed. However, I disagree with that assessment for numerous methodological reasons. First heterogeneity is not study size independent: smaller meta-analyses are more often homogeneous and larger studies are heterogeneous (for both methodological and practical reasons). So according to this mantra we will be filtering out the most valuable analyses, the ones that involve many studies, over the much smaller ones. In addition, random effects models can model that heterogeneity and account for it. Finally, large heterogeneity is the norm and it\'s great if it has been picked up and can be incorporated in the model. It is much more problematic when the underlying heterogeneity is not picked up and studies are \"safely\" combined under a homogeneity assumption. In other words, small meta-analyses of "homogeneous" studies are much more problematic than large "heterogeneous" ones as evidenced in this <http://www.ncbi.nlm.nih.gov/pubmed/23922860>. In smaller meta-analyses existing heterogeneity is just not picked up well enough. The uncertainty of the estimate becomes obvious if the CIs for I\^2 are reported, as argued in <http://www.ncbi.nlm.nih.gov/pubmed/17974687>.

Response: Thank you for your expert comment. We used random-effect mode in meta-analysis and the confidence interval for I\^2 is now provided in the manuscript.

Reviewer \#3:

The manuscript \[PONE-D-20-13736\] entitled "Distribution, antifungal susceptibility pattern and intra-Candida albicans species complex prevalence of Candida africana: A systematic review and meta-analysis" reviewed and discussed a general view about the prevalence and susceptibility pattern of Candida albicans species complex.

1- The title, aim and body of manuscript are not concise and coherent. Moreover, there were a surprisingly high number of spelling mistakes considering this standard of writing. Manuscript needs to be a major revision of English editing, preferably by a native speaker/editor.

Response: Thank you for your comment. The manuscript has been extensively revised based on your comments and those of reviewers \#1 and \#2. Furthermore, to improve English language usage, the manuscript was revised by a native English speaker who is active in the field.

2- Authors mentioned Due to the limited knowledge concerning the prevalence and antifungal susceptibility pattern of this species, a comprehensive study is needed in this regard.

Major comments, manuscript is a superficial paper and has poorly prepared "head and tail". Based on ref. 30, Candida africana Vulvovaginitis: Prevalence and Geographical Distribution. J Mycol Med. 2020:100966, recently has been already published in this particular region. What is new in this particular paper?

Response: We believe that the current study is significantly different to the in press article cited by the reviewer (Fakhim et al., 2020), and is such is a useful addition to the existing literature. The article by Fakhim et al. is a cross-sectional study, despite its title which suggests a review article. In that article, there are no data pertaining to the search strategies employed or search terms, and importantly any inclusion/exclusion criteria. Importantly, their literature search spanned 1991 to 2019, commencing a full decade before Candida africana had been officially described in 2001 (Mycoses. 2001;44(11-12):437-445). Thus, they included data for isolates which had not been robustly identified and were considered to be atypical Candida albicans isolates. The current study explicitly excluded all such isolates from the analyses, ensuring that only data from genuine C. africana isolates was included.

Additionally, in the present work although the period of search is 10 years less than the article quoted by the reviewer, it identified 41 relevant articles (10 records more than in the cited article) of which 31 have data on prevalence (fig 1). The article referred to by the reviewer was cited in our study, and references cited in it cross-checked to further ensure no relevant article has been missed.

Finally, in addition to all the above points, our study answers the question "How common Candida africana is within the Candida albicans species complex?". We provide clear data concerning overall and geographical location-specific data pertaining to intra-complex prevalence of Candida africana whereas the article quoted by the reviewer focused principally on incidence (and not prevalence).

3- As presented, it does not merit acceptance. It is more suitable for a local journal. It is agreed that this could be a useful contribution to the literature but not just yet-there simply is not enough data to be of any practical use.

Response: We are somewhat confused by this point, especially in light of our responses to the previous comments from this reviewer. The current study is not a regional analysis on prevalence, rather a detailed meta-analysis of reported occurrence/presence and prevalence of C. africana within the C. albicans species complex globally. As such, we do not really understand why the reviewer thinks that this analysis would be more suited to a "local journal". Based on the points mentioned in response to the above comment, we believe that the data generated in our article would be of interest to researchers working on Candida around the world, especially since we have collated all of the available data from the time of official description of C. africana (2001) to 2020 without any geographical limitations.

4- Interpretation and conclusions: derived from the data.

Response: Thank you for supporting our conclusion.

5- References: up to date and relevant.

Response: Thank you for your support.

6- Abstract reflects the content of the paper

Response: Thank you for your support.

7- Limited number of terms (i.e., key words) used to conduct searches was presented, what may lead to an underestimate of the general picture of the evidence base available for analysis. The number of terms used to conduct searches, including MeSH terms and free terms should be developed.

Response: Unfortunately, there is no Mesh term for Candida africana. We optimized the current search strategy after numerous modifications and the best results were obtained using the current combination of search terms. In response to your comment, we have since consulted with an experienced librarian and another expert in the subject of this article and they have confirmed the validity of the search terms we have used. Finally, as a further "control" to ensure that our search algorithms did not miss any literature, we also examined all of the literature cited in all of the articles identified in our searches. These points have now been highlighted in the revised manuscript.
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Dear Dr. Mahmoudi,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Joy Sturtevant

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: All comments were addressed in a satisfactory manner.

Just a few minor grammatical mistakes need to be fixed:

Lines 31 and 127: Change \"Honduran\" to \"Honduras\"

Line 214: Change \"wile-type\" to \"wild-type\"

Line 215: Change \"has been\" to \"have been\"

Reviewer \#2: I am happy with the changes to the manuscript and the authors\' responses. Well done, I hope you feel the review process improved the quality of the manuscript.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: **Yes: **Hamid Badali
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Dear Dr. Mahmoudi:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff
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Dr. Joy Sturtevant
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